IGM Biosciences Inc at Wolfe Research Healthcare Conference (Virtual) Transcript
Well, good afternoon, everyone. We are continuing our Wolfe Healthcare Conference and our fireside chat series. I have the opportunity to host Fred, CEO of IGM Biosciences. This is an incredibly exciting company. It's trying to do something that really has never been done before when we think about bispecific antibodies and just really an antibody platform in general.
I'll tell you, for us, when we look at companies that we get involved in, particularly in oncology, we pick our bets very selectively. And the 2 things that kind of stand out to me as we've done work here is, if this company can do half of what they're really striving to do, this will be something that becomes extremely important from a strategic perspective. But also, I think and this is really what I look forward to digging with Fred on is, what have we now started to see even with the ASH abstracts in terms of proof-of-concept, in terms of modulating an immune response that can not only have a read across the CD20 x CD3, which look I'm
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |